V
Vifor Pharma AG
SIX:VIFN
Vifor Pharma AG
SIX:VIFN
Price:
166.15 CHF
0.48%
Market Closed
Updated:
May 2, 2024
Vifor Pharma AG
Operating Income
|
Vifor Pharma AG
Operating Income Peer Comparison
Comparables:
NOVN
NLSP
ROG
S
SDZ
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
V
|
Vifor Pharma AG
SIX:VIFN
|
Operating Income
CHf351.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
Novartis AG
SIX:NOVN
|
Operating Income
$12.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Operating Income
-$15.5m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Operating Income
CHf18.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Operating Income
$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vifor Pharma AG's Operating Income?
Operating Income
351.8m
CHF
351.8m
CHF
Based on the financial report for Dec 31, 2021, Vifor Pharma AG's Operating Income amounts to 351.8m CHF.
What is Vifor Pharma AG's Operating Income growth rate?
Operating Income CAGR 10Y
1%
1%
Over the last year, the Operating Income growth was 35%. The average annual Operating Income growth rates for Vifor Pharma AG have been 16% over the past three years , 8% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
